arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

HCW Biologics Inc.

HCWB
$1.03 ▼ -0.09 (-7.59%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

HCW Biologics Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4M
Dividend Yield —
Revenue Growth 1758.5% ↘
Op. Margin None
ROIC -42.6% ↘
FCF / Share $-2.99 ↘
Trailing P/E —
Price / Book 0.2x
FCF Yield —
Debt / Equity 0.88
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$121.73K
↑ +1758.5% —
Net Income Profit after all expenses
$3.47M
— 0.0% —
Operating Margin Operating profit as % of sales
49.8%
↑ +122.4% —
FCF / Share Free cash flow per share
$-2.99
↓ -928.7% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
0
Financial Health ↑
18
Cash Quality ↑
83

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters